New England Research Institutes (NERI) and ProMedica Clinical Research Center, two contract research organisations (CROs) based around Boston, US, have announced a strategic alliance covering a range of clinical trial services from Phases I through to IV.
Formerly the Phase I/II unit of MTRA Clinical Research Center, ProMedica is a dedicated Phase I specialist whose capabilities include bioavailability, bioequivalence, pharmacodynamic, pharmacokinetic, tolerance, toxicity, gastrointestinal absorption, interaction and first-in-human studies.
Founded in 1986, NERI has a track record in Phase II-IV trials, offering services such as study feasibility, protocol design, project management, regulatory affairs, clinical monitoring and training, biostatistics, data management, site selection, recruitment and quality assurance.
The alliance will enable the CROs to offer pharmaceutical, medical device, biotechnology and biomaterial clients “seamless and comprehensive clinical research solutions for Phase I-IV studies in a variety of therapeutic areas”, they said.
